Aclaris Therapeutics (ACRS) Cash & Equivalents (2014 - 2026)

Aclaris Therapeutics' Cash & Equivalents history runs 13 years deep, the most recent figure standing at $28.7 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 5.59% year-over-year to $28.7 million in Q1 2026; TTM through Mar 2026 was $28.7 million, a 5.59% decrease from a year earlier, with the FY2025 full-year figure at $20.0 million, down 18.76% from the prior year.
• Cash & Equivalents climbed to $28.7 million in Q1 2026 per ACRS's latest filing, from $20.0 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $68.3 million in Q2 2022 and bottomed at $20.0 million in Q4 2025.
• The 5-year median for Cash & Equivalents is $35.8 million (2024), against an average of $36.9 million.
• Across the five-year window, Cash & Equivalents jumped 65.55% in 2022 and plunged 54.37% in 2023, its largest moves.
• Year by year, Cash & Equivalents stood at $45.3 million in 2022, then slipped by 11.92% to $39.9 million in 2023, then slumped by 38.39% to $24.6 million in 2024, then declined by 18.76% to $20.0 million in 2025, then jumped by 43.59% to $28.7 million in 2026.
• Per Business Quant, the three latest ACRS Cash & Equivalents figures stand at $28.7 million (Q1 2026), $20.0 million (Q4 2025), and $25.3 million (Q3 2025).